Intriguingly, it was reported that tamoxifen, prescribed to breast cancer patients, may inhibit TrkANGF phosphorylation and, respectively, the NGF-elicited proliferation of epithelial cells from breast cancer [82]. The gene discussed is NGF; the disease is breast carcinoma.